T1	PROC 46 85	Estudio para la eficacia y la seguridad
T2	DISO 128 169	hipercolesterolemia familiar homocigótica
T3	CHEM 263 273	alirocumab
#1	AnnotatorNotes T3	C3491162; alirocumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T4	PROC 192 219	Estudio sin enmascaramiento
T5	PROC 225 259	evaluar la eficacia y la seguridad
#2	AnnotatorNotes T5	C0511730; Identify product efficacy and safety issues; Health Care Activity
T6	DISO 302 343	hipercolesterolemia familiar homocigótica
T7	PROC 540 548	tratados
#3	AnnotatorNotes T7	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T8	DISO 367 408	Hipercolesterolemia familiar homocigótica
T9	DISO 521 525	HFho
T10	PROC 447 475	diagnosticados genéticamente
#4	AnnotatorNotes T10	C0596612; genetic disorder diagnosis; Diagnostic Procedure
T11	DISO 480 519	hipercolesterolemia familiar homocigota
#5	AnnotatorNotes T11	C0342881; Homozygous Familial Hypercholesterolemia; Disease or Syndrome
T12	CHEM 570 579	estatinas
#6	AnnotatorNotes T12	C0075191; statine; Amino Acid, Peptide, or Protein | C0360714; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Organic Chemical · Pharmacologic Substance
T13	PROC 590 623	terapias modificadoras de lípidos
T14	CHEM 616 623	lípidos
#7	AnnotatorNotes T14	C0023779; Lipids; Organic Chemical
T15	CHEM 640 649	estatinas
#8	AnnotatorNotes T15	C0075191; statine; Amino Acid, Peptide, or Protein | C0360714; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Organic Chemical · Pharmacologic Substance
T16	CHEM 664 673	estatinas
#9	AnnotatorNotes T16	C0075191; statine; Amino Acid, Peptide, or Protein | C0360714; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Organic Chemical · Pharmacologic Substance
T17	CHEM 743 750	lípidos
#10	AnnotatorNotes T17	C0023779; Lipids; Organic Chemical
T18	PROC 769 793	consentimiento informado
#11	AnnotatorNotes T18	C0567423; Informed consent for procedure; Therapeutic or Preventive Procedure
T19	PROC 899 907	aféresis
#12	AnnotatorNotes T19	C2599009; LDL apheresis procedure; Therapeutic or Preventive Procedure | C0949035; Low density lipoprotein apheresis; Therapeutic or Preventive Procedure
T20	PROC 919 949	tratamiento de aféresis de LDL
T21	PROC 632 635	TML
#13	AnnotatorNotes T21	C0585943; Lipid-lowering therapy; Therapeutic or Preventive Procedure (?) [lipid modifying therapy]
T22	CHEM 1124 1129	C-LDL
#14	AnnotatorNotes T22	C0023824; LDL Cholesterol Lipoproteins; Biologically Active Substance · Organic Chemical
T23	PROC 1251 1262	tratamiento
#15	AnnotatorNotes T23	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T24	PROC 1285 1288	TML
#16	AnnotatorNotes T24	C0585943; Lipid-lowering therapy; Therapeutic or Preventive Procedure (?) [lipid modifying therapy]
T25	CHEM 1324 1333	estatinas
#17	AnnotatorNotes T25	C0075191; statine; Amino Acid, Peptide, or Protein | C0360714; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Organic Chemical · Pharmacologic Substance
T26	CHEM 1365 1374	estatinas
#18	AnnotatorNotes T26	C0075191; statine; Amino Acid, Peptide, or Protein | C0360714; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Organic Chemical · Pharmacologic Substance
T27	CHEM 1420 1429	estatinas
#19	AnnotatorNotes T27	C0075191; statine; Amino Acid, Peptide, or Protein | C0360714; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Organic Chemical · Pharmacologic Substance
T28	DISO 1659 1687	diabetes mellitus tipo 1 o 2
T29	PROC 1342 1345	TML
#20	AnnotatorNotes T29	C0585943; Lipid-lowering therapy; Therapeutic or Preventive Procedure (?) [lipid modifying therapy]
T30	DISO 1719 1738	enfermedad tiroidea
#21	AnnotatorNotes T30	C0040128; Thyroid Diseases; Disease or Syndrome
T31	DISO 1779 1791	hipertensión
#22	AnnotatorNotes T31	C0020538; Hypertensive disease; Disease or Syndrome
T32	PROC 1357 1360	TML
#23	AnnotatorNotes T32	C0585943; Lipid-lowering therapy; Therapeutic or Preventive Procedure (?) [lipid modifying therapy]
T33	CHEM 1809 1822	Triglicéridos
#24	AnnotatorNotes T33	C0041004; Triglycerides; Biologically Active Substance · Organic Chemical
T34	PROC 2110 2131	Creatina fosfoquinasa
#25	AnnotatorNotes T34	C0201973; Creatine kinase measurement; Laboratory Procedure
T35	DISO 1860 1879	Insuficiencia renal
#26	AnnotatorNotes T35	C0035078; Kidney Failure; Disease or Syndrome | C1565489; Renal Insufficiency; Disease or Syndrome
T36	PROC 1897 1935	tasa de filtración glomerular estimada
#27	AnnotatorNotes T36	C3811844; Estimated Glomerular Filtration Rate; Laboratory Procedure
T37	PROC 1937 1941	eGFR
#28	AnnotatorNotes T37	C0C3811844; Estimated Glomerular Filtration Rate; Laboratory Procedure
T38	PROC 730 750	analítica de lípidos
T39	PROC 2024 2027	ALT
#29	AnnotatorNotes T39	C0201836; Alanine aminotransferase measurement; Laboratory Procedure
T40	PROC 2031 2057	aspartato aminotransferasa
#30	AnnotatorNotes T40	C0201899; Aspartate aminotransferase measurement; Laboratory Procedure
T41	PROC 2133 2136	CPK
#31	AnnotatorNotes T41	C0201973; Creatine kinase measurement; Laboratory Procedure
T42	CHEM 89 99	alirocumab
#32	AnnotatorNotes T42	C3491162; alirocumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T43	PROC 1274 1282	aféresis
#33	AnnotatorNotes T43	C2599009; LDL apheresis procedure; Therapeutic or Preventive Procedure | C0949035; Low density lipoprotein apheresis; Therapeutic or Preventive Procedure
T44	CHEM 946 949	LDL
#34	AnnotatorNotes T44	C0023823; Low-Density Lipoproteins; Biologically Active Substance · Organic Chemical
T45	PROC 1113 1129	niveles de C-LDL
T46	PROC 625 628	TML
#35	AnnotatorNotes T46	C0585943; Lipid-lowering therapy; Therapeutic or Preventive Procedure (?) [lipid modifying therapy]
T47	ANAT 1483 1491	corporal
#36	AnnotatorNotes T47	C0460148; Human body structure; Anatomical Structure | C1318419; Entire human body; Anatomical Structure
T48	DISO 1401 1413	intolerantes
#37	AnnotatorNotes T48	C0277585; Intolerance to drug; Pathologic Function
T49	ANAT 1730 1738	tiroidea
#38	AnnotatorNotes T49	C0040132; Thyroid Gland; Body Part, Organ, or Organ Component | C1278878; Entire thyroid gland; Body Part, Organ, or Organ Component
T50	PROC 1809 1832	Triglicéridos en ayunas
#39	AnnotatorNotes T50	C3835804; serum or plasma triglycerides fasting; Therapeutic or Preventive Procedure
T51	ANAT 1874 1879	renal
#40	AnnotatorNotes T51	C0022646; Kidney; Body Part, Organ, or Organ Component | C1278978; Entire kidney; Body Part, Organ, or Organ Component
T52	PROC 1998 2022	Alanina aminotransferasa
#41	AnnotatorNotes T52	C0201836; Alanine aminotransferase measurement; Laboratory Procedure
T53	PROC 2059 2062	AST
#42	AnnotatorNotes T53	C0201899; Aspartate aminotransferase measurement; Laboratory Procedure
T54	Date 13 17	2017
T55	LIVB 103 108	niños
#43	AnnotatorNotes T55	C0008059; Child; Age Group
T57	LIVB 277 282	niños
#44	AnnotatorNotes T57	C0008059; Child; Age Group
T58	LIVB 437 446	Pacientes
#45	AnnotatorNotes T58	C0030705; Patients; Patient or Disabled Group
T59	LIVB 530 539	Pacientes
#46	AnnotatorNotes T59	C0030705; Patients; Patient or Disabled Group
T60	Neg_cue 636 639	sin
T62	DISO 653 663	no toleran
#47	AnnotatorNotes T62	C0277585; Intolerance to drug; Pathologic Function
T63	Dose 676 690	dosis estables
T64	Duration 699 717	al menos 4 semanas
T65	LIVB 831 837	padres
#48	AnnotatorNotes T65	C0015671; Father (person); Family Group | C0030551; parent; Family Group
T67	LIVB 865 873	paciente
#49	AnnotatorNotes T67	C0030705; Patients; Patient or Disabled Group
T68	LIVB 886 895	pacientes
#50	AnnotatorNotes T68	C0030705; Patients; Patient or Disabled Group
T69	Date 912 918	actual
T70	Date 950 958	en curso
T71	Duration 978 996	al menos 4 semanas
T72	Duration 1048 1064	al menos 6 meses
T73	LIVB 1099 1108	Pacientes
#51	AnnotatorNotes T73	C0030705; Patients; Patient or Disabled Group
T76	LIVB 1227 1235	paciente
#52	AnnotatorNotes T76	C0030705; Patients; Patient or Disabled Group
T77	Neg_cue 1361 1364	sin
T78	LIVB 1391 1400	pacientes
#53	AnnotatorNotes T78	C0030705; Patients; Patient or Disabled Group
T79	Duration 1439 1457	al menos 4 semanas
T80	LIVB 1461 1470	Pacientes
#54	AnnotatorNotes T80	C0030705; Patients; Patient or Disabled Group
T81	LIVB 1511 1520	Pacientes
#55	AnnotatorNotes T81	C0030705; Patients; Patient or Disabled Group
T82	Age 1521 1534	de 8 a 9 años
T83	Neg_cue 1535 1537	no
T84	LIVB 1563 1572	pacientes
#56	AnnotatorNotes T84	C0030705; Patients; Patient or Disabled Group
T85	Age 1573 1588	de 10 a 17 años
T86	LIVB 1645 1654	Pacientes
#57	AnnotatorNotes T86	C0030705; Patients; Patient or Disabled Group
T88	LIVB 1705 1714	Pacientes
#58	AnnotatorNotes T88	C0030705; Patients; Patient or Disabled Group
T89	LIVB 1765 1774	Pacientes
#59	AnnotatorNotes T89	C0030705; Patients; Patient or Disabled Group
T95	LIVB 111 123	adolescentes
#60	AnnotatorNotes T95	C0205653; Adolescent (age group); Age Group
T98	LIVB 285 297	adolescentes
#61	AnnotatorNotes T98	C0205653; Adolescent (age group); Age Group
T56	PROC 1478 1491	peso corporal
#62	AnnotatorNotes T56	C2985231; Body Weight Measurement; Diagnostic Procedure
T66	PROC 1554 1560	Tanner
#63	AnnotatorNotes T66	C0431029; Tanner bone age assessment; Diagnostic Procedure
T74	PROC 1618 1624	Tanner
#64	AnnotatorNotes T74	C0431029; Tanner bone age assessment; Diagnostic Procedure
T75	PHYS 1905 1926	filtración glomerular
#65	AnnotatorNotes T75	C0232809; Glomerular filtration; Organ or Tissue Function
T61	ANAT 1916 1926	glomerular
#66	AnnotatorNotes T61	C0022663; Kidney Glomerulus; Body Part, Organ, or Organ Component | C1284485; Entire glomerulus; Body Part, Organ, or Organ Component
T87	PROC 1976 1995	visita de selección
#67	AnnotatorNotes T87	C1710477; Trial Screening; Research Activity + C1512346; Patient Visit; Health Care Activity
T90	PROC 1009 1028	visita de selección
#68	AnnotatorNotes T90	C1710477; Trial Screening; Research Activity + C1512346; Patient Visit; Health Care Activity
A1	Population_data T55 Age
A2	Population_data T95 Age
A3	Population_data T98 Age
A4	Population_data T57 Age
A5	Assertion T15 Negated
A7	Assertion T26 Negated
A6	Status T30 History_of
#69	AnnotatorNotes T1	C0511730; Identify product efficacy and safety issues; Health Care Activity
#70	AnnotatorNotes T4	C1709323; Open Label Study; Research Activity 
#71	AnnotatorNotes T9	C0342881; Homozygous Familial Hypercholesterolemia; Disease or Syndrome
#72	AnnotatorNotes T6	C0342881; Homozygous Familial Hypercholesterolemia; Disease or Syndrome
#73	AnnotatorNotes T2	C0342881; Homozygous Familial Hypercholesterolemia; Disease or Syndrome
#74	AnnotatorNotes T8	C0342881; Homozygous Familial Hypercholesterolemia; Disease or Syndrome
#75	AnnotatorNotes T28	C0011854; Diabetes Mellitus, Insulin-Dependent; Disease or Syndrome + C0011860; Diabetes Mellitus, Non-Insulin-Dependent; Disease or Syndrome
#76	AnnotatorNotes T13	C0585943; Lipid-lowering therapy; Therapeutic or Preventive Procedure (?) [lipid modifying therapy]
#77	AnnotatorNotes T38	C0851512; Lipid analyses; Laboratory Procedure 
#78	AnnotatorNotes T69	C0521116; Current (present time); Temporal Concept 
#79	AnnotatorNotes T20	C2599009; LDL apheresis procedure; Therapeutic or Preventive Procedure | C0949035; Low density lipoprotein apheresis; Therapeutic or Preventive Procedure
#80	AnnotatorNotes T45	C0202117; Low density lipoprotein cholesterol measurement; Laboratory Procedure
T91	Observation 848 860	asentimiento
A8	Assertion T91 Negated
#81	AnnotatorNotes T91	C1302239; Patient consented to clinical trial; Finding
T92	Neg_cue 844 847	sin
T94	Observation 656 663	toleran
T96	Neg_cue 1792 1794	no
T97	Neg_cue 1688 1690	no
T99	Quantifier_or_Qualifier 1691 1701	controlada
A10	Assertion T99 Negated
T100	Quantifier_or_Qualifier 1795 1805	controlada
A11	Assertion T100 Negated
T101	Result_or_Value 1541 1550	estadío 1
A12	Assertion T101 Negated
R1	Negation Arg1:T97 Arg2:T99	
R2	Negation Arg1:T83 Arg2:T101	
R3	Negation Arg1:T60 Arg2:T15	
R5	Negation Arg1:T92 Arg2:T91	
R6	Negation Arg1:T77 Arg2:T26	
R7	Negation Arg1:T96 Arg2:T100	
R4	Experiences Arg1:T55 Arg2:T42	
R8	Experiences Arg1:T95 Arg2:T42	
R9	Experiences Arg1:T55 Arg2:T2	
R10	Experiences Arg1:T95 Arg2:T2	
R11	Experiences Arg1:T57 Arg2:T3	
R12	Experiences Arg1:T98 Arg2:T3	
R13	Experiences Arg1:T57 Arg2:T6	
R14	Experiences Arg1:T98 Arg2:T6	
R15	Experiences Arg1:T58 Arg2:T11	
R16	Experiences Arg1:T58 Arg2:T9	
R17	Experiences Arg1:T59 Arg2:T7	
R18	Used_for Arg1:T12 Arg2:T7	
R19	Experiences Arg1:T59 Arg2:T13	
R20	Experiences Arg1:T59 Arg2:T46	
R21	Experiences Arg1:T59 Arg2:T21	
R23	Combined_with Arg1:T12 Arg2:T13	
R24	Combined_with Arg1:T12 Arg2:T46	
T93	Neg_cue 653 655	no
A9	Assertion T94 Negated
R25	Negation Arg1:T93 Arg2:T94	
R26	Experiences Arg1:T59 Arg2:T62	
R28	Overlap Arg1:T94 Arg2:T16	
R29	Causes Arg1:T16 Arg2:T62	
R31	Experiences Arg1:T59 Arg2:T38	
R32	Has_Dose_or_Strength Arg1:T16 Arg2:T63	
R33	Has_Duration_or_Interval Arg1:T16 Arg2:T64	
R34	Before Arg1:T16 Arg2:T38	
T102	PROC 754 763	selección
#82	AnnotatorNotes T102	C0242802; Patient Selection; Research Activity
R35	Overlap Arg1:T38 Arg2:T102	
R36	Before Arg1:T16 Arg2:T102	
R37	Overlap Arg1:T15 Arg2:T62	
R39	Experiences Arg1:T68 Arg2:T19	
R40	Experiences Arg1:T68 Arg2:T20	
R41	Overlap Arg1:T20 Arg2:T69	
R42	Overlap Arg1:T20 Arg2:T70	
R43	Before Arg1:T20 Arg2:T90	
T103	Quantifier_or_Qualifier 970 977	estable
#83	AnnotatorNotes T103	C0205360; Stable status; Qualitative Concept
R44	Has_Duration_or_Interval Arg1:T103 Arg2:T71	
R45	Before Arg1:T103 Arg2:T90	
R46	Has_Quantifier_or_Qualifier Arg1:T20 Arg2:T103	
R47	Has_Duration_or_Interval Arg1:T20 Arg2:T72	
R48	Before Arg1:T19 Arg2:T90	
R49	Experiences Arg1:T73 Arg2:T45	
T104	Result_or_Value 1130 1166	inferiores a 130 mg/dl (3,37 mmol/l)
R50	Has_Result_or_Value Arg1:T45 Arg2:T104	
T105	PROC 1199 1208	selección
#84	AnnotatorNotes T105	C0242802; Patient Selection; Research Activity
R51	Overlap Arg1:T45 Arg2:T105	
R52	After Arg1:T45 Arg2:T23	
T106	Quantifier_or_Qualifier 1263 1270	estable
#85	AnnotatorNotes T106	C0205360; Stable status; Qualitative Concept
R53	Has_Quantifier_or_Qualifier Arg1:T23 Arg2:T106	
R54	Experiences Arg1:T73 Arg2:T23	
T107	Quantifier_or_Qualifier 1375 1383	estables
#86	AnnotatorNotes T107	C0205360; Stable status; Qualitative Concept
A13	Assertion T107 Negated
R55	Has_Quantifier_or_Qualifier Arg1:T26 Arg2:T107	
R56	Negation Arg1:T77 Arg2:T107	
R57	Experiences Arg1:T73 Arg2:T43	
R58	Has_Quantifier_or_Qualifier Arg1:T43 Arg2:T106	
R59	Has_Quantifier_or_Qualifier Arg1:T24 Arg2:T106	
R60	Experiences Arg1:T73 Arg2:T24	
R61	Used_for Arg1:T25 Arg2:T24	
R62	Combined_with Arg1:T25 Arg2:T29	
R63	Experiences Arg1:T73 Arg2:T32	
R65	Causes Arg1:T27 Arg2:T48	
R66	Experiences Arg1:T78 Arg2:T48	
R67	Has_Duration_or_Interval Arg1:T26 Arg2:T79	
R68	Has_Duration_or_Interval Arg1:T32 Arg2:T79	
R69	Has_Duration_or_Interval Arg1:T29 Arg2:T79	
R70	Has_Duration_or_Interval Arg1:T25 Arg2:T79	
R71	Has_Duration_or_Interval Arg1:T43 Arg2:T79	
R72	Experiences Arg1:T78 Arg2:T32	
R73	Experiences Arg1:T78 Arg2:T26	
R74	Experiences Arg1:T80 Arg2:T56	
R75	Location_of Arg1:T47 Arg2:T56	
T108	Result_or_Value 1492 1508	inferior a 25 kg
R76	Has_Result_or_Value Arg1:T56 Arg2:T108	
R77	Has_Age Arg1:T81 Arg2:T82	
R78	Has_Result_or_Value Arg1:T66 Arg2:T101	
R79	Experiences Arg1:T81 Arg2:T66	
R80	Has_Age Arg1:T84 Arg2:T85	
T109	Result_or_Value 1595 1614	mínimo en estadío 2
R81	Has_Result_or_Value Arg1:T74 Arg2:T109	
R82	Experiences Arg1:T84 Arg2:T74	
R83	Has_Quantifier_or_Qualifier Arg1:T28 Arg2:T99	
R84	Experiences Arg1:T86 Arg2:T28	
R85	Experiences Arg1:T88 Arg2:T30	
R86	Location_of Arg1:T49 Arg2:T30	
T110	Quantifier_or_Qualifier 1739 1752	descontrolada
A14	Status T110 History_of
#87	AnnotatorNotes T110	C0205318; Uncontrolled; Qualitative Concept
R87	Has_Quantifier_or_Qualifier Arg1:T30 Arg2:T110	
R88	Experiences Arg1:T89 Arg2:T31	
R89	Has_Quantifier_or_Qualifier Arg1:T31 Arg2:T100	
T111	Result_or_Value 1833 1857	>350 mg/dl (3,95 mmol/l)
R90	Has_Result_or_Value Arg1:T50 Arg2:T111	
T112	Observation 1823 1832	en ayunas
#88	AnnotatorNotes T112	C0015663; Fasting; Finding
R91	Overlap Arg1:T50 Arg2:T112	
R92	Location_of Arg1:T51 Arg2:T35	
T113	Quantifier_or_Qualifier 1880 1885	grave
#89	AnnotatorNotes T113	C1547227; Severe - Severity of Illness Code; Intellectual Product
R93	Has_Quantifier_or_Qualifier Arg1:T35 Arg2:T113	
R95	Location_of Arg1:T61 Arg2:T75	
R96	Location_of Arg1:T61 Arg2:T36	
R97	Location_of Arg1:T61 Arg2:T37	
T114	Result_or_Value 1943 1968	<30 ml / min / 1.73 m ^ 2
R100	Has_Result_or_Value Arg1:T36 Arg2:T114	
R101	Has_Result_or_Value Arg1:T37 Arg2:T114	
T115	Result_or_Value 2064 2107	>2 x límite superior de la normalidad (LSN)
R106	Has_Result_or_Value Arg1:T53 Arg2:T115	
R107	Has_Result_or_Value Arg1:T40 Arg2:T115	
R108	Has_Result_or_Value Arg1:T52 Arg2:T115	
R109	Has_Result_or_Value Arg1:T39 Arg2:T115	
T116	Result_or_Value 2138 2146	>3 x LSN
R110	Has_Result_or_Value Arg1:T34 Arg2:T116	
R111	Has_Result_or_Value Arg1:T41 Arg2:T116	
R112	Experiences Arg1:T59 Arg2:T15	
R27	Experiences Arg1:T59 Arg2:T94	
T117	Quantifier_or_Qualifier 1313 1320	estable
#90	AnnotatorNotes T117	C0205360; Stable status; Qualitative Concept
T118	CONC 1300 1305	dosis
#91	AnnotatorNotes T118	C0178602; Dosage; Quantitative Concept
R30	Has_Quantifier_or_Qualifier Arg1:T118 Arg2:T117	
R113	Used_for Arg1:T118 Arg2:T25	
T119	Quantifier_or_Qualifier 1346 1354	estables
#92	AnnotatorNotes T119	C0205360; Stable status; Qualitative Concept
R114	Has_Quantifier_or_Qualifier Arg1:T29 Arg2:T119	
R22	Overlap Arg1:T37 Arg2:T87	
R38	Overlap Arg1:T36 Arg2:T87	
#93	AnnotatorNotes T70	C0521116; Current (present time); Temporal Concept
A15	Experiencer T55 Patient
A16	Experiencer T95 Patient
A17	Experiencer T57 Patient
A18	Experiencer T98 Patient
A19	Experiencer T58 Patient
A20	Experiencer T59 Patient
A21	Assertion T62 Hypothetical
A22	Assertion T16 Hypothetical
A23	Assertion T63 Hypothetical
A24	Assertion T64 Hypothetical
A25	Experiencer T65 Patient
A26	Experiencer T67 Patient
A27	Experiencer T68 Patient
A28	Experiencer T73 Patient
A29	Experiencer T76 Patient
A30	Experiencer T78 Patient
A31	Experiencer T80 Patient
A32	Experiencer T81 Patient
A33	Experiencer T84 Patient
A34	Experiencer T86 Patient
A35	Experiencer T88 Patient
A36	Experiencer T89 Patient
